Cargando…

P06 Pharmacokinetics and renal accumulation of VRP-034

BACKGROUND: Nephrotoxicity is a dose-limiting factor for polymyxin B (PMB), a last-line therapy for MDR Gram-negative bacterial infections. The majority of the filtered PMB undergoes extensive tubular reabsorption leading to significant accumulation of the drug in tubular cells, causing renal tubula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vishwakarma, Kamlesh Kumar, Chilbule, Rahul, Chaudhary, Manu, Sharma, Arun, Chaudhary, Saransh, Aggarwal, Anmol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Posters Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849352/ http://dx.doi.org/10.1093/jacamr/dlac004.005

Ejemplares similares

P07 Toxicokinetic profile of VRP-034
por: Murkunde, Yogeshkumar Vishnupant, et al.
Publicado: (2022)

P05 In vivo efficacy of VRP-034 in lung and thigh infection models
por: Vishwakarma, Kamlesh Kumar, et al.
Publicado: (2022)

Polymyxin B-Induced Kidney Injury Assessment of a Novel Formulation of Polymyxin B (VRP-034) in Rats
por: Roy, Dilip, et al.
Publicado: (2021)

Bioequivalence of a biosimilar enoxaparin (Cloti‐Xa™) and its innovator (Clexane(®)): A single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, balanced study in healthy human subjects
por: Saxena, Sumit, et al.
Publicado: (2022)

Protective role of ceftriaxone plus sulbactam with VRP1034 on oxidative stress, hematological and enzymatic parameters in cadmium toxicity induced rat model
por: Dwivedi, Vivek Kumar, et al.
Publicado: (2012)

1373. Activity of Ceftriaxone–Sulbactam–EDTA Against Multi-Drug-resistant A. baumannii, P. aeruginosa and Enterobacteriaceae Isolates (WHO Critical Priority Pathogens) Collected from Various Hospitals in India
por: Girotra, Ruchi, et al.
Publicado: (2018)

1984. Ceftriaxone-Sulbactam-EDTA vs. Meropenem: Analysis of Failed Patients With Assessment of MIC Increases and Changes in Genotypic Profile in PLEA (a Phase 3, Randomized, Double-Blind Clinical Trial in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis)
por: Mir, Mohd Amin, et al.
Publicado: (2018)

1959. Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes in Patients Infected With Ceftriaxone Non-Susceptible, Extended-Spectrum β-Lactamase and Multi-Drug-resistant Pathogens at Baseline
por: Mir, Mohd Amin, et al.
Publicado: (2018)

1974. Ceftriaxone-Sulbactam-EDTA vs. Meropenem in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes by Baseline MIC in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis
por: Mandale, Pankaj, et al.
Publicado: (2018)

P034. Technostress and primary headache: psychosocial risk
por: Pucci, Ennio, et al.
Publicado: (2015)

P034 Inter-scorer concordance impacts MSLT results
por: Eriksson, N, et al.
Publicado: (2021)

PW03-034 – How to classify autoinflammatory diseases?
por: Grateau, G, et al.
Publicado: (2013)

PW01-034 – Clinical-genetic investigation of FMF in Armenia
por: Hayrapetyan, H, et al.
Publicado: (2013)

P034: Daily observation rounds to assess the practice for patients isolated because of diarrhea
por: Mikkelsen, R, et al.
Publicado: (2013)

P-034: EFFECTS OF HYDROXYUREA ON SKELETAL MUSCLE MICROVASCULATURE OF MICE WITH SICKLE CELL DISEASE
por: M., RICCETTI, et al.
Publicado: (2022)

VRP in urban areas to optimize costs while mitigating environmental impact
por: Cerrone, Carmine, et al.
Publicado: (2022)

PW02-034 - NLRP3 mosaicism detection in CAPS using NGS
por: Stoffels, M, et al.
Publicado: (2013)

P01-034 – Cancer in FMF: a population based study Israel
por: Brenner, R, et al.
Publicado: (2013)

Designing an Energy-Efficient Transportation Network to Transport Perishable Crops: An Aggregated VRP and X-means Clustering Approach
por: Rahul, Joydev Karmakar, et al.
Publicado: (2023)

P034 Measurement Type Moderates the Relationship between Sleep and Aggression: A Meta-Analytic Investigation
por: Demichelis, O, et al.
Publicado: (2022)

06. United States Healthcare Provider Preferences for Adult Pneumococcal Vaccine Recommendations
por: Vietri, Jeffrey, et al.
Publicado: (2021)

Opération piquet PO 2000-034
por: Royer, J P
Publicado: (2000)

Magnetostructural transformation and magnetocaloric effect of Sn-bonded Mn(0.66)Fe(0.34)Ni(0.66)Fe(0.34)Si(0.66)Ge(0.34) composite
por: Si, Yu, et al.
Publicado: (2018)

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
por: Geibel, Brooke, et al.
Publicado: (2020)

Title unknown, CERN-ALEPH-2001-034
por: CERN. Geneva. ALEPH
Publicado: (2001)

Characterisation of the role of Vrp1 in cell fusion during the development of visceral muscle of Drosophila melanogaster
por: Eriksson, Therese, et al.
Publicado: (2010)

P1020: SELINEXOR (SEL) PLUS RUXOLITINIB (RUX) IN JAK INHIBITOR (JAKI) TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS: UPDATED RESULTS FROM XPORT-MF-034
por: Ali, Haris, et al.
Publicado: (2023)

Sexual Dysfunction in perimenopausal women
por: Aziz, Sadaf, et al.
Publicado: (2022)

P06 Working differently – ‘Accepting Me’
por: Clarke, Lindsey
Publicado: (2022)

1298. Population Pharmacokinetics of Ceftazidime-avibactam among Critically-ill Patients with and without Receipt of Continuous Renal Replacement Therapy
por: Kline, Ellen G, et al.
Publicado: (2020)

1087. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients with Augmented Renal Clearance (ARC)
por: Fratoni, Andrew J, et al.
Publicado: (2021)

The VrrA sRNA controls a stationary phase survival factor Vrp of Vibrio cholerae
por: Sabharwal, Dharmesh, et al.
Publicado: (2015)

P06-06. Capacity building for HIV vaccine trials in Africa through South-South collaboration
por: Mpendo, J, et al.
Publicado: (2009)

Study of the three body matrix element of the neutralino decay 034
por: Chouridou, S, et al.
Publicado: (2002)

LBODP034 Metformin Associated Lactic Acidosis, Rare But Real
por: Khalifa, Maram, et al.
Publicado: (2022)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS malignancies consortium clinical trials 010 and 034
por: Chadburn, A, et al.
Publicado: (2009)

P06 Waldenström macroglobulinemia – beware the label of primary Raynaud’s Phenomenon
por: Gor, Shivani, et al.
Publicado: (2021)

1319. Pharmacokinetics of Ceftolozane/Tazobactam in Patients with Burns
por: Hall, Ronald G, et al.
Publicado: (2020)

Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment
por: Parasrampuria, Ridhi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nf278mvn2l60r7ojfv9milvneu